
Affinity Biopharma is a global, clinical stage biopharmaceutical company focused on advancing innovative technology and first-in-class anti-tumor treatment. We have established Tumor MicroEnvironment Activated (TMEA) platform technology including TMEA-SMDC, TMEAbody®, TMEAkine® and TMEA-ICE® platforms, which allow selective unleash of the drug in the tumor microenvironment, reducing “On target, off tumor toxicity” and dramatically improving the therapeutic index. Affinity’s proprietary TMEA platform® could be broadly applied to therapeutic small molecules, cytokines, antibodies, fusion…
Annual Revenue$50M to $100M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.